Cipla Ltd Q4 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/2300wdqsu82elk1yar1dy3s9.pdf

Key Takeaways


U.S. Business & the Derisking Imperative

The derisking pipeline

Vohra: "The value stays intact as no new generic is expected before we launch."

Facility Status & Remediation


One India & Consumer Health

Vohra: "We are seeing a pretty strong Tier 2 to 6 growth, and that is feeding some of our products that are in the areas of respiratory and anti-infectives because those are the type of products that will deepen in India."

Margins & Cost Structure


Capital Allocation & Portfolio Strategy

Vohra: "If you look at our overall capital allocation priority, I think India continues to be our priority. So the whole -- the disproportionate part of capital, we would look to invest in India for the growth that is available out here."

Pipeline & Respiratory Strategy

Vohra: "Our strategy is to try and file every product that we are doing on the respiratory side from 2 sites and not 1."

Guidance & Commitments

CommitmentSpecificsTimeline
Indore facility classificationFinal FDA classification expectedMay 2023
Goa CAPA completionCAPA completed, reinspection targeted for Q3End of Q1 FY24
U.S. base business quarterly run-rate$190–195 mn trajectoryOngoing
Full-year consolidated EBITDA margin22% or thereaboutFY24
R&D spend6%–6.5% of revenueFY24
Consumer health EBITDA marginHigher range of mid-teen to double-digitFY24
Consumer health margin graduationToward company averageNext 2–3 years
Nanopaclitaxel supply from two sitesTwo-site supply establishedBy FY25
Symbicort filingANDA submissionQ4 FY24
Three differentiated product filingsClinical trials ongoing, filings targetedFY24

Key Metrics

MetricQ4 FY23
Revenue₹5,739 cr, +9% YoY reported, +14% ex-COVID
Full-year revenue₹22,753 cr, +5% YoY reported, +11% ex-COVID
EBITDA margin20%+ reported for Q4; full year 22% reported, 23% adjusted for COVID
Gross margin64%, +480 bps YoY driven by new launches and mix change
Profit after tax₹526 cr (9.2% of sales); adjusted PAT ₹708 cr (12.3% of sales) after one-time impairment charge
Full-year PAT₹2,802 cr reported; adjusted PAT ₹2,984 cr (13.1% of sales)
Effective tax rate24% adjusted
R&D investment₹371 cr (6.5% of revenue), +15% YoY; full year ₹1,344 cr
North America revenue$200 mn+ in Q4, first time crossing this threshold; full year $733 mn, +23% YoY
U.S. respiratory revenue$160 mn for FY23
One India franchise growth16% ex-COVID in Q4
India consumer franchise annual run-rate₹1,000 cr+
Lanreotide market share17%
ROIC (trailing 12 months)~24%, above long-term range of 17%–20%
Field force~10,000 total, roughly 7,000 MRs and 3,000 others; grew by 800+ over FY22–23